Switch to:

Key Ratios

New Key Statistics Module, Z-Score and F-Score
Market Cap $M514Revenue (TTM) $M15.0Net Margin (%)-411.4Altman Z-Score20.3
Enterprise Value $M151EPS (TTM) $-0.5Operating Margin %-432.4Piotroski F-Score1
P/E(ttm)--Beneish M-Score180Pre-tax Margin (%)-411.4Higher ROA y-yN
Price/Book1.310-y EBITDA Growth Rate %-25.6Quick Ratio27.4Cash flow > EarningsN
Price/Sales34.25-y EBITDA Growth Rate %-26.5Current Ratio27.4Lower Leverage y-yY
Price/Free Cash Flow--y-y EBITDA Growth Rate %--ROA % (ttm)-14.2Higher Current Ratio y-yN
Dividend Yield %--PEG--ROE % (ttm)-14.7Less Shares Outstanding y-yN
Payout Ratio %--Shares Outstanding M137ROIC % (ttm)-3,362.6Gross Margin Increase y-yN

Gurus Latest Trades with ACHN

Number of guru portfolios checked: 69.
Ticker Guru Date Action
Impact Price Range
Current Price Change from Average Comment Current Shares

ACHN is held by these investors:

ACHN: Insider Buys/Sells

Click Here for All Insider Trades.
InsiderPosition Date Trades Shares Trade Price ($) Change (%) Details
FISHERMAN JASON SDirector 2016-12-22Buy10,000$3.96-5.05view
Fenton Mary KayCFO 2016-12-05Buy2,500$4.11-8.52view
Truitt JosephChief Commercial Officer 2016-12-02Buy3,500$4.06-7.39view
MANNING MARTHA EEVP, General Counsel 2016-12-02Buy2,500$4.09-8.07view
Deshpande MilindCEO 2016-12-02Buy2,500$4.06-7.39view
Barrish Joel CChief Scientific Officer 2016-12-02Buy2,500$4.06-7.39view
Apelian DavidChief Medical Officer 2015-12-30Sell10,000$10.5-64.19view
Fenton Mary KayCFO 2015-12-28Sell43,500$10.08-62.7view
VITULLO NICOLEDirector 2015-11-11Sell550,000$10.17-63.03view
VITULLO NICOLEDirector 2015-09-25Sell9,310$8.22-54.26view

Press Releases about ACHN :

Quarterly/Annual Reports about ACHN:

News about ACHN:

Articles On GuruFocus.com
Steven Cohen Increases Position in Dynavax Oct 07 2016 
UBS and JMP Securities Downgrade Achillion Pharmaceuticals Inc.(ACHN) Following Johnson & Johnson (J May 21 2015 
Dycom Industries (DY) Surpasses Estimates; Achillion Pharma (ACHN) Inks Mega-Deal with Janssen May 20 2015 
Gilead Experiencing Bumpy Ride Despite Strong Fundamentals Apr 03 2015 
Achillion Pharmaceuticals Stock Soars Following Successful Mid-Stage Hep C Drug Combo Trial Feb 10 2015 
Hall of Fame/ Hall of Shame: The Best and Worst Recommendations of 2014 Jan 09 2015 
Weekly CEO Sells Highlight: Achillion Pharmaceutical Inc, Protective Life Corp, Host Hotels & Resort Aug 25 2014 
Top 4 Insider Buys of Last Week Jun 10 2013 
Weekly CEO Sells Highlight: Achillion Pharmaceuticals Inc, Monster Beverage Corp, CarMax Inc, and Im Jan 23 2012 
Weekly CEO Sells Highlight: UNH, LRY, ACHN, RPM Jan 16 2012 

More From Other Websites
USPTO Grants Composition of Matter Patent to Achillion for Small Molecule Complement Alternative... Mar 21 2017
Achillion Pharmaceuticals, Inc. :ACHN-US: Earnings Analysis: Q4, 2016 By the Numbers : March 7, 2017 Mar 07 2017
These 5 Stocks Under $10 Could Explode Up Soon Mar 02 2017
Achillion Pharmaceuticals to Support a Natural History Study of C3 Glomerulopathy, a Rare Renal... Feb 28 2017
Achillion (ACHN) Reports Narrower-Than-Expected Q4 Loss Feb 27 2017
Biotech Movers: Cempra Flys High On Phase Three Results Feb 24 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 24 2017
Achillion reports 4Q loss Feb 23 2017
Achillion reports 4Q loss Feb 23 2017
ACHILLION PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... Feb 23 2017
ACHILLION PHARMACEUTICALS INC Files SEC form 10-K, Annual Report Feb 23 2017
Achillion Reports 2016 Fourth Quarter and Year-End Financial Results Feb 23 2017
Biotech's Rally Continues to Build in 2017: Today's Reports on Achillion Pharmaceuticals and... Feb 22 2017
Achillion to Present at the Leerink Partners 6th Annual Global Healthcare Conference Feb 13 2017
Achillion Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ACHN-US :... Feb 03 2017
Premarket Biotech Movers: Cytokinetics, Achillion, Qiagen Feb 02 2017
Coverage initiated on Achillion Pharma by Ladenburg Thalmann Feb 02 2017
Blog Coverage FDA Approved Orphan Drug Designation for TG Therapeutics' Combination of TG-1101 and... Jan 25 2017
Achillion Pharmaceuticals, Inc. – Value Analysis (NASDAQ:ACHN) : January 11, 2017 Jan 11 2017

Add Notes, Comments

If you want to ask a question or report a bug, please create a support ticket.
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)